Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.500-1.580 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of recent analyst reports. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Wolfe Research started coverage on shares of Repligen in a research note on Thursday. They issued a “peer perform” rating on the stock. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Price Performance

Shares of Repligen stock traded down $4.47 during trading on Thursday, hitting $146.00. 72,515 shares of the stock traded hands, compared to its average volume of 657,177. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average is $141.59 and its 200-day moving average is $144.78. The stock has a market cap of $8.18 billion, a price-to-earnings ratio of -406.66, a PEG ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.23 EPS. Research analysts expect that Repligen will post 1.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.